Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)

Trial Profile

Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2013

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Hypereosinophilic syndrome; Polycythaemia vera
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Dec 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2013 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 04 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top